The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Open accessAbstract
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating patients into four risk groups ('low', 'intermediate', 'high', 'very high risk') with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a 'gene-only model' ('Model-2') was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulated iron metabolism is a hallmark of a large subset of MDS with ringed sideroblasts (MDS-RS), characterized by aberrant iron accumulation in erythroblast mitochondria and accounting for ~30% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of MDS, eprenetapopt is currently only indicated in ~7% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Haferlach et al. 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Several Tests for Model Specification in the Presence of Alternative Hypotheses
Davidson, R., & MacKinnon, J. G. (1981) · Econometrica · doi:10.2307/1911522 · Cited by 1,747
Flagged first, then by citations
Research works printed but not linked: 1
- Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, eds World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001; pp 61–73.
Cited by
Sorted by citations
Items 701–800 of 999
Li, B., Liu, J., Xu, Z., Qin, T., Shi, Z., Song, Z., Huang, H., Fang, L., Zhang, H., Pan, L., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.15036 · Cited by 14
Acute myeloid leukemia in a father and son with a germline mutation of ASXL1
Seiter, K. P., Htun, K. Z., Baskind, P., & Liu, Z. (2018) · Biomarker Research · doi:10.1186/s40364-018-0121-3 · Cited by 15
Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes
Shingai, N., Harada, Y., Iizuka, H., Ogata, Y., Doki, N., Ohashi, K., Hagihara, M., Komatsu, N., & Harada, H. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2551-y · Cited by 15
Improving Treatment for Myelodysplastic Syndromes Patients
Montoro, M. J., Yerlikaya, A., Ali, A. M., & Raza, A. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0583-4 · Cited by 14
L’hématopoïèse clonale : un concept émergent à la croisée des spécialités
Danlos, F., Papo, M., & Micol, J. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.05.005 · Cited by 19
Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS
Wang, X., Song, X., & Yan, X. (2019) · Medicine · doi:10.1097/md.0000000000015743 · Cited by 14
Du, M., Xu, M., Deng, J., Liu, L., Guo, T., Xia, L., Hu, Y., & Mei, H. (2019) · Journal of Cancer · doi:10.7150/jca.30363 · Cited by 14
Jajosky, A. N., Sadri, N., Meyerson, H. J., Oduro, K. A., Kelkar, A., FitzGerald, B. J., Tomlinson, B. K., Moore, E. M., & Beck, R. C. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13574 · Cited by 14
Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy
Maher, M., Diesch, J., Pannérer, M.-M. L., & Buschbeck, M. (2021) · Cancers · doi:10.3390/cancers13071746 · Cited by 14
Killick, S. B., Wiseman, D. H., Quek, L. S., Cargo, C. A., Culligan, D. J., Enright, H., Green, S., Ingram, W. A., Jones, G. L., Kell, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17621 · Cited by 14
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Stahl, M. F., & Zeidan, A. M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1297704 · Cited by 13
Getting personal with myelodysplastic syndromes: is now the right time?
Chokr, N., Pine, A. B., Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1592673 · Cited by 13
Janusz, K., Izquierdo, M. M., Cadenas, F. L., Ramos, F., Hernández-Sánchez, J. M., Lumbreras, E., Robledo, C., Sánchez‐del‐Real, J., Caballero, J. C., Collado, R., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-020-04360-4 · Cited by 13
Xie, Z., Chen, E. C., Stahl, M. F., & Zeidan, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101033 · Cited by 13
Lee, W., Lin, C., Tsai, C., Tien, F., Lo, M., Ni, S., Yao, M., Tseng, M., Kuo, Y., Liu, M.-C., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26799 · Cited by 13
Sendker, S., Awada, A., Domagalla, S., Sendker, M., Orhan, E., Hoffmeister, L. M., Antoniou, E., Niktoreh, N., Reinhardt, D., Neuhoff, N. V., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01919-8 · Cited by 13
ArCH: improving the performance of clonal hematopoiesis variant calling and interpretation
Chan, I. C. C., Panchot, A., Schmidt, E., McNulty, S. N., Wiley, B. J., Liu, J., Turner, K., Moukarzel, L. A., Wong, W. S. W., Tran, D., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae121 · Cited by 14
Aakash, F., Gisriel, S. D., Zeidan, A. M., Bennett, J. M., Bejar, R. L., Bewersdorf, J. P., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100615 · Cited by 14
Yakoub‐Agha, I., & Deeg, J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.06.023 · Cited by 13
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
Martín, I., Such, E., Navarro, B., Villamón, E., Vicente, A., Mora, E., Pedrola, L., Ibáñez, M., López‐Pavía, M., Tormo, M., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0016-9 · Cited by 13
Noy‐Lotan, S., Krasnov, T., Dgany, O., Jeison, M., Yanir, A. D., Gilad, O., Toledano, H., Barzilai‐Birenboim, S., Yacobovich, J., Izraeli, S., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17285 · Cited by 13
Gu, S., Xia, J., Tian, Y., Zi, J., & Ge, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-07864-y · Cited by 13
Zhang, R., Wang, L., Chen, P., Gao, X., Wang, S., Li, F., Dou, L., Gao, C., Li, Y., & Liu, D. (2021) · Cancer Medicine · doi:10.1002/cam4.3763 · Cited by 13
Ferrone, C. K., Wong, H., Semenuk, L., Werunga, B., Snetsinger, B., Zhang, X., Zhang, G. Y., Lui, J., Richard‐Carpentier, G., Crocker, S. F., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.07.010 · Cited by 13
The Mutational Landscape of Myeloid Leukaemia in Down Syndrome
de Castro, C. P. M., Cadefau-Fabregat, M., & Cuartero, S. (2021) · Cancers · doi:10.3390/cancers13164144 · Cited by 16
Chan, O., Ali, N. E. A., Sallman, D. A., Padron, E., Lancet, J. E., & Komrokji, R. S. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.002 · Cited by 15
Myelodysplastic Syndrome: Diagnosis and Screening
Tria, F., Ang, D. C., & Fan, G. (2022) · Diagnostics · doi:10.3390/diagnostics12071581 · Cited by 13
Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician
Lai, C., Bhansali, R. S., Kuo, E., Mannis, G. N., & Lin, R. J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390018 · Cited by 13
Biology of peripheral T cell lymphomas – Not otherwise specified: Is something finally happening?
Maura, F., Dodero, A., Carniti, C., & Bolli, N. (2016) · Pathogenesis · doi:10.1016/j.pathog.2016.02.002 · Cited by 13
Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., & Haferlach, C. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22377 · Cited by 13
Self-citationEvans, A. G., Aḥmad, A., Burack, R., & Iqbal, M. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.104 · Cited by 13
Palau, A., Mallo, M., Palomo, L., Hernández‐Rodríguez, I., Diesch, J., Campos, D., Granada, I., Juncà, J., Drexler, H. G., Solé, F. G., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22430 · Cited by 13
Patel, S. S., Sekeres, M. A., & Nazha, A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1307361 · Cited by 13
Yokoyama, K., Shimizu, E., Yokoyama, N., Nakamura, S., Kasajima, R., Ogawa, M., Takei, T., Ito, M., Kobayashi, A., Yamaguchi, R., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017010744 · Cited by 13
Self-citationMiao, Y., Li, B., Ding, L., Zhu, H., Luo, C., Wang, J., Luo, C., & Chen, J. (2019) · European Journal of Pediatrics · doi:10.1007/s00431-019-03468-8 · Cited by 13
Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges
Caponetti, G. C., & Bagg, A. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13284 · Cited by 14
Liu, M., Wang, F., Zhang, Y., Chen, X., Cao, P., Nie, D., Fang, J., Wang, M., Liu, M., & Liu, H. (2021) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2021-0002 · Cited by 13
The myelodysplastic syndromes: the era of understanding
Meers, S. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12443 · Cited by 14
Guerenne, L., Beurlet, S., Said, M., Gorombei, P., Pogam, C. L., Guidez, F., de la Grange, P., Omidvar, N., Vanneaux, V., Mills, K., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0235-8 · Cited by 13
Zhang, T., Xu, Y. Y., Pan, J., Li, H., Wang, Q., Wen, L., Wu, D., Sun, A., & Chen, S. (2017) · Leukemia · doi:10.1038/leu.2017.228 · Cited by 13
Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies
Trivedi, G., Inoue, D., & Zhang, L. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.013 · Cited by 14
Snow, A. E., & Zeidner, J. F. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221112899 · Cited by 12
Ren, Y., Lang, W., Mei, C., Luo, Y., Ye, L., Wang, L., Zhou, X., Xu, G., Ma, L., Jin, J., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3099 · Cited by 12
Albitar, F. S., Ma, W., Diep, K., Dios, I. D., Agersborg, S. S., Thangavelu, M., Brodie, S., & Albitar, M. X. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0278 · Cited by 12
Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki
Taguchi, M., Mishima, H., Shiozawa, Y., Hayashida, C., Kinoshita, A., Nannya, Y., Makishima, H., Horai, M., Matsuo, M., Sato, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219386 · Cited by 12
Self-citationPediatric Myelodysplastic Syndromes
Patel, S. S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.03.015 · Cited by 13
Is Myelodysplasia a Consequence of Normal Aging?
Heibl, S., Stauder, R., & Pfeilstöcker, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01136-5 · Cited by 14
Majeti, R., Jamieson, C. H. M., Pang, W. W., Jaiswal, S., Leeper, N. J., Wernig, G., & Weissman, I. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-104436 · Cited by 12
Liu, X., Zou, Y., Zhang, L., Guo, Y., Chen, Y., Yang, W., Chen, X., Wang, S., Zhang, Y., Ruan, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841179 · Cited by 12
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
Leone, P. G., Fabiani, E., & Voso, M. T. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2022.030 · Cited by 14
Risk stratifying MDS in the time of precision medicine
Cazzola, M. (2022) · Hematology · doi:10.1182/hematology.2022000349 · Cited by 12
Marvin‐Peek, J., Mason, E. F., Kishtagari, A., Jayani, R., Dholaria, B., Kim, T. K., Engelhardt, B. G., Chen, H., Strickland, S. A., Savani, B. N., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.008 · Cited by 12
VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view
Heiblig, M., Patel, B. A., & Jamilloux, Y. (2023) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2023.101861 · Cited by 12
Myelodysplastic features in a patient with germline CEBPA-mutant acute myeloid leukaemia
Yan, B., Ng, C., Moshi, G. B., Ban, K. H.-K., Lee, P.-L., Seah, E., Chiu, L., Koay, E. S., Liu, T.-C., Ng, C. H., et al. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203672 · Cited by 12
Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome
Wu, D., Yao, D., Yang, L., Ma, J., Wen, X., Yang, J. C., Guo, H. Y., Li, X., Qian, W., Lin, J., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1187273 · Cited by 12
Jafari, P. A., Sadeghian, M. H., Miri, H. H., Sadeghi, R., Bagheri, R., Lavasani, S., & Souri, S. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102832 · Cited by 12
Wang, W. T., Auer, P. L., Zhang, T., Spellman, S. R., Carlson, K.-S., Nazha, A., Bolon, Y., & Saber, W. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.04.027 · Cited by 12
Ganguly, B. B., & Mandal, S. (2017) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2017.10.004 · Cited by 11
Symeonidis, A. S., Chatzilygeroudi, T., Chondrou, V., & Sgourou, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416069 · Cited by 11
Clinical and Mechanistic Implications of R-Loops in Human Leukemias
Lee, S. Y., Miller, K. M., & Kim, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065966 · Cited by 11
Toribio-Castelló, S., Castaño, S., Villaverde-Ramiro, Á., Such, E., Arnán, M., Solé, F. G., Díaz‐Beyá, M., Díez‐Campelo, M., Rey, M. D., González, T., et al. (2023) · Cancers · doi:10.3390/cancers15153822 · Cited by 11
The evolution of preclinical models for myelodysplastic neoplasms
Mina, A. A., Pavletic, S. Z., & Aplan, P. D. (2024) · Leukemia · doi:10.1038/s41375-024-02181-2 · Cited by 11
Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics
Santoro, N., Salutari, P., Ianni, M. D., & Marra, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084259 · Cited by 10
Choi, I. Y., Ling, J. P., Zhang, J., Helmenstine, E., Walter, W., Tsakiroglou, P., Bergman, R. E., Philippe, C., Manley, J. L., Rouault‐Pierre, K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011260 · Cited by 12
Self-citationWhole-exome sequencing enhances prognostic classification of myeloid malignancies
Ruffalo, M., Husseinzadeh, H. D., Makishima, H., Przychodzen, B. P., Ashkar, M., Koyutürk, M., Maciejewski, J. P., & LaFramboise, T. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.10.003 · Cited by 11
Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia
Joshi, K., Zhang, L., Breslin, P., & Zhang, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_5 · Cited by 14
Insights into novel emerging epigenetic drugs in myeloid malignancies
Chandhok, N. S., & Prébet, T. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719866081 · Cited by 11
Atypical CML- the role of morphology and precision genomics
Lasho, T. L. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101133 · Cited by 11
Yan, X., Wang, L., Jiang, L., Luo, Y., Lin, P., Yang, W., Ren, Y., Ma, L., Zhou, X., Mei, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3786 · Cited by 11
The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies
Gurnari, C., Pagliuca, S., & Visconte, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063135 · Cited by 12
Li, X., Xu, F., Zhang, Z., Guo, J., He, Q., Song, L., Wu, D., Zhou, L.-Y., Su, J., Xiao, C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01157-8 · Cited by 11
Jiang, L., Ye, L., Ma, L., Ren, Y., Zhou, X., Mei, C., Xu, G., Yang, H., Lu, C., Luo, Y., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03905-y · Cited by 11
Sakhdari, A., Class, C. A., Bravo, G. M., Sasaki, K., Bueso-Ramos, C., Patel, K. P., Routbort, M. J., Loghavi, S., Ok, C. Y., Quesada, A. E., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01074-y · Cited by 11
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
Cassanello, G., Pasquale, R., Barcellini, W., & Fattizzo, B. (2022) · Cancers · doi:10.3390/cancers14194941 · Cited by 11
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome
Kunimoto, H., Miura, A., Maeda, A., Tsuchida, N., Uchiyama, Y., Kunishita, Y., Nakajima, Y., Takase‐Minegishi, K., Yoshimi, R., Miyazaki, T., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03598-8 · Cited by 11
Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis
Demir, D. (2023) · Genes · doi:10.3390/genes14071424 · Cited by 11
Hogg, G., Severson, E. A., Cai, L. J., Hoffmann, H. M., Holden, K. A., Fitzgerald, K. D., Kenyon, A. L., Zeng, Q., Mooney, M. R., Gardner, S. A., et al. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.07.006 · Cited by 11
Khanna, V., Lü, R., Kumar, J., Molina, A., Stehr, H., Spiteri, E., Spinner, M. A., Silva, O., Fernandez‐Pol, S., Tan, B. T., et al. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107433 · Cited by 11
Gioacchino, E., Zhang, W., Koyunlar, C., Zink, J., de Looper, H. W. J., Gussinklo, K. J., Hoogenboezem, R., Bosch, D. A., Bindels, E., Touw, I. P., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19585 · Cited by 11
Clinicopathologic Effect of DNMT3A Mutation in Adult T-Cell Acute Lymphoblastic Leukemia
Aref, S., Menshawy, N. E., El-Ghonemy, M. S., Abouzeid, T., & ElBaiomy, M. A. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.11.003 · Cited by 12
Magotra, M., Sakhdari, A., Lee, J. S., Tomaszewicz, K., Dresser, K., Hutchinson, L., Woda, B. A., & Chen, B. J. (2016) · Histopathology · doi:10.1111/his.13046 · Cited by 11
Therapeutic targeting of RNA splicing in myelodysplasia
Kim, Y. J., & Abdel-Wahab, O. I. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.007 · Cited by 11
Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
Drusbosky, L. M., & Cogle, C. R. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0412-z · Cited by 11
Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis
Karner, K. H., George, T. I., & Patel, J. L. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.6.509 · Cited by 11
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1819233 · Cited by 11
Daw, S., & Law, S. (2020) · Environmental Toxicology · doi:10.1002/tox.23020 · Cited by 11
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
Gonzalez‐Lugo, J. D., Chakraborty, S., Verma, A., & Shastri, A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.003 · Cited by 11
Waidhauser, J., Labopin, M., Esteve, J., Kröger, N. M., Cornelissen, J. J., Gedde‐Dahl, T., van Gorkom, G. N. Y., Finke, J., Rovira, M., Schaap, N. P., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01322-w · Cited by 11
De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features
Epstein-Peterson, Z. D., Spitzer, B. G., Derkach, A., Arango, J. E., McCarter, J. G. W., Medina-Martinez, J. S., McGovern, E. M., Farnoud, N. R., Levine, R. L., & Tallman, M. S. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106857 · Cited by 11
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014; Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018). in AMl, RBM39…”
RNA Splicing as a Therapeutic Target in Cancer
Lewis, A. M., Weis, K., & Abdel-Wahab, O. I. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-035809 · Cited by 11
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
Bewersdorf, J. P., Mina, A. A., Stahl, M. F., & Zeidan, A. M. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01141-2 · Cited by 13
Figg, J., Barajas, J. M., & Obeng, E. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000632 · Cited by 10
Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes
Meunier, M., Laurin, D., & Park, S. (2023) · Cells · doi:10.3390/cells12040658 · Cited by 11
Li, X., Li, W., Zhang, Y., Xu, L., & Song, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101150 · Cited by 11
van Spronsen, M. F., Gassen, S. V., Duetz, C., Westers, T. M., Saeys, Y., & van de Loosdrecht, A. A. (2024) · Leukemia · doi:10.1038/s41375-024-02203-z · Cited by 10
Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies
Bauer, M., Schöbel, C.-M., Wickenhauser, C., Seliger, B., & Jasinski‐Bergner, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386993 · Cited by 11
Aberrant pre-mRNA processing in cancer
Biswas, J., Boussi, L. S., Stein, E. M., & Abdel-Wahab, O. I. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230891 · Cited by 10
A common structural mechanism for RNA recognition by the SF3B complex in mRNA splicing and export
Zhang, Y., Yin, C., Wang, Y., Yan, K., Zhao, B., Hu, X., Wan, Y., Cheng, H., & Huang, J. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf759 · Cited by 10
Spliceosomal factor mutations and mis-splicing in MDS
Hershberger, C. E., Daniels, N. J., & Padgett, R. A. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101199 · Cited by 10
Metadata
- Authors
- Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H. P., Klein, H.-U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W., & Ogawa, S.
- Affiliations
- Munich Leukemia Laboratory (Germany) (DE)
- Kyoto University (JP)
- The University of Tokyo (JP)
- Research Center for Advanced Science and Technology, The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Cedars-Sinai Medical Center (US)
- University of Münster (DE)
- Corresponding author
- Haferlach, T
- Ogawa, S
- ORCID
- Venue
- Leukemia
- Published
- 2013-11-13
- Volume
- 28
- Issue
- 2
- Pages
- 241-247
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3918868
- OpenAlex
- W2026134786
- Cited by
- 1,532
- References
- 32
- Citations by year
- 2026: 56 · 2025: 85 · 2024: 102 · 2023: 132 · 2022: 133 · 2021: 177 · 2020: 167 · 2019: 134 · 2018: 117 · 2017: 136 · 2016: 126 · 2015: 105 · 2014: 56 · 2013: 3
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- Leukemia (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Public Health Service (08C46598A)
- Japan Society for the Promotion of Science (24390242, 24659458, 21790907, 25670446, 24221011, 23249052)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- myelodysplastic syndrome, somatic mutations, prognostic model, risk stratification, TET2, SF3B1, ASXL1, SRSF2, DNMT3A, RUNX1, PRPF8, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gene Frequency, Genetic Markers, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
